Table 1.
Baseline Characteristics and Data on COVID-19-Related Hospitalization of the Studied Population (n = 100 Patients)
| Baseline Characteristics | Total (n = 100) |
|---|---|
| Gender female, No. (%) | 41 (41) |
| Age, y | |
| Median (IQR) | 67.5 (56–78.5) |
| Range | 24–90 |
| Charlson comorbidity index, median (IQR) | 3 (1–4) |
| Hypertension, No. (%) | 50 (50) |
| Diabetes, No. (%) | 21 (21) |
| COPD, No. (%) | 12 (12) |
| CHD, No. (%) | 12 (12) |
| CKD, No. (%) | 7 (7) |
| Obesity, No. (%) | 25 (25) |
| Length of hospital stay, median (IQR), d | 16 (8–27) |
| Time to microbiological cure, median (IQR), da | 27 (14–44) |
| Treatments, No. (%) | |
| Antiretrovirals (LPV/r, DRV/c) | 76 (76) |
| Hydroxychloroquine | 88 (88) |
| Remdesivir | 9 (9) |
| Immune-modulators | 48 (48) |
| High-dose steroid (≥1 mg/kg 6-MP) | 26 (26) |
| Antibiotics | 49 (49) |
| ICU admission, No. (%) | 31 (31) |
| Highest oxygen supplementation, No. (%) | |
| No support | 13 (13) |
| Standard oxygen therapy | 33 (33) |
| High flow nasal cannulae | 7 (7) |
| Noninvasive ventilation | 26 (26) |
| Mechanical ventilation | 21 (21) |
| COVID-19 severity (WHO), No. (%) | |
| Mild | 9 (9) |
| Moderate | 32 (32) |
| Severe | 12 (12) |
| Critical | 47 (47) |
| Follow-up timing, median (IQR) | |
| Days since symptoms onset | 82 (70–101) |
| Days since hospital discharge | 60 (48–67) |
| Days since microbiological cure | 50 (36–66) |
Abbreviations: CHD, coronary heart disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; LPV/r, lopinavir/ritonavir; DRV/c, darunavir/cobicistat; ICU, intensive care unit; IQR, interquartile range; WHO, World Health Organization.
aTime from the first positive to the first negative nasopharyngeal swab.